Shop
eStoreRx™
Online Supplement Dispensary
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
Biotics Research is proud to expand our commitment to education with the Wellness Unfiltered Pro Podcast. Each episode delves into key health topics and the clinical applications of our premier products. Through candid, insightful conversations, our team offers practical guidance to keep you informed and empowered as a healthcare professional.
November 14 2024
Exciting research is being done in the burgeoning field called Metabolic Psychiatry, which is dedicated to addressing the bioenergetic underpinnings o...
Results of a double-blind randomized and placebo-controlled trial evaluating the use of omega-3 fatty acid supplementation among people with systemic lupus erythematosus (SLE) were recently published in Lupus Science & Medicine. 78 adults (97% women) with active SLE were randomized to receive either control (vegetable oil, including olive, palm kernel, and corn oil) or 4 g per day of krill oil concentrate (KOC). Each gram of KOC provided 322 mg of total omega-3 fatty acids (193 mg EPA and 96 mg DHA), as well as 601 mg of phospholipids (including 558 mg of phosphatidylcholine), for a total daily dose of 1288 mg omega-3s. The randomization period of the study was 24 weeks, followed by an open-label extension period, with the omega-3 index as its primary endpoint and clinical features including the SLE Disease Activity Index 2000 (SLEDAI-2K) as secondary endpoints.
The majority of study participants had a low or intermediate omega-3 index at baseline, including 38% that had levels below 4%, associated with greater cardiovascular disease mortality risk. While no significant change was observed with placebo, KOC supplementation raised the omega-3 index above 4% in all participants, and above 6% in 90% of participants after 24 weeks. Regarding the secondary outcomes, although SLEDAI-2K scores did not change significantly between groups, a subset with more severe disease activity experienced a significant improvement in weeks 4, 8, and 16 compared to placebo (but not at week 24). No other significant differences were observed, other than a lower adverse effect rate in the KOC group. Overall, this study suggests KOC effectively increases the omega-3 index among people with SLE, potentially reducing cardiovascular disease risk and perhaps reducing disease activity among people with more severe SLE, though this has not been conclusively shown.
Submit this form and you'll receive our latest news and updates.
A report on the intake of fish and omega-3 fatty acids among pregnant women in the U.S. was recently published in Public...
Learn moreA dose-response meta-analysis of randomized controlled trials on omega-3 polyunsaturated fatty acids (PUFAs) and blood p...
Learn moreA meta-analysis describing the dosing relationship between omega-3 fatty acid supplementation and blood pressure was rec...
Learn more
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment